Treatment of coronavirus pneumonia the combination of the hydroxychloroquine and azithromycin was successfully tested on several hundred patients at the university hospital of Marseille, said Professor Eric Chabrières March 27, in live TV channel LCI.
Chabrières working at the Mediterranean Institute of infectious diseases, University hospital of Marseille, announced during the live discussion: “Following the publication last week of our article about the test of the combination of hydroxychloroquine/azithromycin in a small group of patients, we decided to use the same Protocol for all comes to us patients with coronavirus infection. We have uploaded all our data treatment. Though they have not yet been finalized, now it can day-by-day to follow our results.”
“Today we treated a patient with 701 COVID-19 and we have only one death [referring to the 86-year —old patient IA Red Spring], that gives a fatality rate of 0.14%. I repeat that this is raw data, but they show a trend. Compare that to 5.8% of patients COVID-19 die from this virus,” — said Eric Chabrier.
See also: There is evidence of treatment success COVID-19 hydroxychloroquine
“Note that none of our patients died of overdoses or side effects of hydroxychloroquine. I think that the debate about the toxicity of this substance is now closed,” added the Professor.
See also: new data on the effects of hydroxychloroquine on SARS-CoV-2
We will remind that the Director of the Mediterranean Institute of infectious diseases Professor Didier Raoult, the team is working with Eric Chabrières, has developed a treatment Protocol coronavirus pneumonia with the use of hydroxychloroquine+azithromycin. Preprints of scientific work performed under his leadership were recently posted on the website of the Institute.